Companies › Immunovant Sciences
2 active drug programs in 7 registered trials: 6 Phase 2, 1 Phase 3; Neurology, Immunology, Metabolic and endocrine; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMVT-1402 | – | Phase 3 | Generalized Myasthenia Gravis; Subacute Cutaneous Lupus Erythematosus; Graves' Disease; Rheumatoid Arthritis … | Apr 2027 |
| Imeroprubart FcγRIIB-FcαRI fusion protein; neonatal Fc receptor (FcRn) inhibitor | FCAR | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06980805 | IMVT-1402 | Phase 2 | Subacute Cutaneous Lupus Erythematosus | Immunology | Apr 2027 |
| NCT07018323 | IMVT-1402 | Phase 2 | Graves' Disease | Metabolic and endocrine | May 2027 |
| NCT06754462 | IMVT-1402 | Phase 2 | Rheumatoid Arthritis | Immunology | Sep 2027 |
| NCT07039916 | IMVT-1402 | Phase 3 | Generalized Myasthenia Gravis | Neurology | Dec 2027 |
| NCT06727604 | IMVT-1402 | Phase 2 | Graves' Disease | Metabolic and endocrine | Jun 2028 |
| NCT06979531 | IMVT-1402 | Phase 2 | Primary Sjögren's Syndrome | Immunology | Jul 2028 |
| NCT07032662 | Imeroprubart | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | Neurology | Aug 2028 |
Cash of $722m on 2026-09-30; operating cash outflow about $416m a year; runway about 21 months at that burn, to Jun 2028; 5 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Oculis Coya Therapeutics NervGen Pharma Cognition Therapeutics Immunic
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.